Your browser doesn't support javascript.
loading
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.
Yang, Qiwei; Madueke-Laveaux, Obianuju Sandra; Cun, Han; Wlodarczyk, Marta; Garcia, Natalia; Carvalho, Katia Candido; Al-Hendy, Ayman.
Afiliação
  • Yang Q; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
  • Madueke-Laveaux OS; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
  • Cun H; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
  • Wlodarczyk M; Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland.
  • Garcia N; Greehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Carvalho KC; Department of Cell Systems and Anatomy, University of Texas Health Science Center, San Antonio, TX 78229, USA.
  • Al-Hendy A; Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento deObstetricia e Ginecologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo 05403-010, Brazil.
Cells ; 13(13)2024 Jun 26.
Article em En | MEDLINE | ID: mdl-38994959
ABSTRACT
Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They have a poor prognosis with high rates of recurrence and metastasis. The five-year survival for uLMS patients is between 25 and 76%, with survival rates approaching 10-15% for patients with metastatic disease at the initial diagnosis. Accumulating evidence suggests that several biological pathways are involved in uLMS pathogenesis. Notably, drugs that block abnormal functions of these pathways remarkably improve survival in uLMS patients. However, due to chemotherapy resistance, there remains a need for novel drugs that can target these pathways effectively. In this review article, we provide an overview of the recent progress in ascertaining the biological functions and regulatory mechanisms in uLMS from the perspective of aberrant biological pathways, including DNA repair, immune checkpoint blockade, protein kinase and intracellular signaling pathways, and the hedgehog pathway. We review the emerging role of epigenetics and epitranscriptome in the pathogenesis of uLMS. In addition, we discuss serum markers, artificial intelligence (AI) combined with machine learning, shear wave elastography, current management and medical treatment options, and ongoing clinical trials for patients with uLMS. Comprehensive, integrated, and deeper insights into the pathobiology and underlying molecular mechanisms of uLMS will help develop novel strategies to treat patients with this aggressive tumor.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Leiomiossarcoma Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Leiomiossarcoma Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article